Document is current

Any future updates will be listed below

Benefits of using SLGT2 Inhibitors for Patients with CDK and DM2 to Reduce Mortality Risks

Crossref DOI link: https://doi.org/10.29328/journal.apps.1001055

Published Online: 2024-05-02

Published Print: 2024-05-02

Update policy: https://doi.org/10.29328/crossmark-policy

About CrossMark